0 Items - $0.00
A to Z

Sp-8-BnT-2'-O-Me-cAMPS / "S-223"

8- Benzylthio- 2'- O- methyladenosine- 3', 5'- cyclic monophosphorothioate, Sp- isomer ( Sp-8-BnT-2'-O-Me-cAMPS / "S-223" ), sodium salt
Selective activator of Epac2 which efficiently discriminates against PKA
Cat. No.: B 056
CAS No.: [pending]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: B 056-01
Unit: 1 µmol / ~0.5 mg

For other salt forms please inquire. According to Schwede et al. (2015), Sp-8-BnT-2'-O-Me-cAMPS is the most potent 2'-substituted activator of Epac2 that efficiently discriminates against Epac1 in vitro (AC50 Epac2 = 1.5 μM (1.8 µM for cAMP) and rel. kmax = 4.3 (1 for cAMP)). Due to the 2'-substitution it is an extremely poor PKA activator and thus allows for specific activation of Epac2 over PKA. In human osteosarcoma U2OS cell lines stably expressing Epac1 or Epac2, Sp-8-BnT-2'-O-Me-cAMPS does not induce Epac signalling at 100 µM, which may be due to inefficient cellular uptake in this biosystem. Detailed technical information available. Reference: Schwede et al., PLoS Biol., 13(1): e1002038 (2015) (Link to PLoS Biology).

Related products: Biolog also offers Sp-8-BnT-cAMPS (Cat. No. B 046 / "S-220") which has increased in vitro and in vivo potency compared to Sp-8-BnT-2'-O-Me-cAMPS, but slight potency to activate PKA, as well as the well-established Epac agonist 8-pCPT-2'-O-Me-cAMP (Cat. No. C 041) which selectively activates Epac1 over Epac2 (Schwede et al. 2015).

Cat. No. B 056
CAS number [pending]
Purity > 98% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Molecular formula C₁₈H₁₉N₅O₅PS₂ · Na
Molecular weight [g/mol] 503.5
cAMP modified at the exocyclic oxygen axial (Sp-)
Modifications 8-cAMP, 2'-cAMP
Target Epac Activator
Lipophilicity 2.87
Absorption max [nm] 283
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 17100
  • 1. Schwede F., Bertinetti D., Langerijs C. N., Hadders M. A., Wienk H., Ellenbroek J. H., de Koning E. J. P., Bos J. L., Herberg F. W., Genieser H.-G., Janssen R. A.Rehmann H., PLoS Biol., 13, 1 - 26 (2015), "Structure-Guided Design of Selective Epac1 and Epac2 Agonists"